首页> 外文会议>International Conference on Science and Technology >Synthesis, In Vitro Anticancer Activity and In Silico Study of some Benzylidene Hydrazide Derivatives
【24h】

Synthesis, In Vitro Anticancer Activity and In Silico Study of some Benzylidene Hydrazide Derivatives

机译:一些苄基肼衍生物的合成,体外抗癌活性和二氧化硅研究

获取原文

摘要

Some benzylidene hydrazides (3a-e) have been synthesized in three reaction steps from anthranilic acid in good yields, about 70-99%. The structures of the synthesized compounds were analyzed using spectroscopic methods. The compounds were evaluated its activity against human lung cancer, A549 cell line by MTT method and studied its molecular docking onto the protein tyrosine kinase (PDB ID: 1M17) by using Molegro~R vs. 5.5. The data showed that N-(2-(2-(4-nitrobenzylidene)hydrazinecarbonyl)phenyl)benzamide (3d) which synthesized in 70% yield and has the highest activity on inhibiting the growth of A549 cell line with IC50 10.9 ug/mL, which was linear with our in silico study. Compound 3d has the smallest RS value -94.44 kcal/mol, lower than selected Ligand, Erlotinib.
机译:一些苄基肼(3A-E)已在三个反应步骤中合成,其优于邻苯二甲酸,产率良好,约70-99%。使用光谱法分析合成化合物的结构。通过MTT方法评估其对人肺癌A549细胞系的活性,通过使用Molegro〜R与5.5研究其在蛋白酪氨酸激酶(PDB ID:1M17)上的分子对接。该数据显示N-(2-(4-(4-(4-(4-硝基苄基)肼羰基)苯基)苯甲酰胺(3D),其合成70%产率,并具有最高的活性,抑制A549细胞系的生长与IC50 10.9 UG / mL ,这与我们在Silico研究中是线性的。复合3D具有最小的Rs值-94.44 kcal / mol,低于选定的配体,erlotinib。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号